维力医疗 20250911 摘要 国内市场方面，维力医疗有哪些新的发展动向？ 在国内市场方面，维力医疗也在进行产品管线升级。例如，在麻醉领域推出可 视双支等新品；在导料领域开发超滑涂层和 BIP 抗菌涂层导尿管，并从留置导 尿管拓展到一次性间歇性导尿管。在泌尿外科方面，不断升级结石清石鞘，并 涉足男性健康相关产品，如包皮缓解器和 ED 治疗仪等。尽管国内反腐环境对 入院销售略有影响，但公司始终未停止产品升级步伐，并持续推进渠道端拓展。 维力医疗主要产品线包括麻醉、导尿和泌尿外科，其中麻醉产品占比最 高，导尿产品以导尿管为主，泌尿外科重点产品为结石抽吸导管。公司 核心业务聚焦于这三大领域。 维力医疗国内外市场收入占比接近五五开。海外市场主要以代工为主， 服务于 Menline、Cardinal、康乐宝、贝朗、美敦力等全球大客户，订 单量稳定增长，并积极拓展新客户。 维力医疗通过丰富代工品类实现海外业务毛利率显著提升。2025 年 4 月关税问题缓解后，海外发货恢复正常，并计划在东南亚布局产能以降 低关税影响，中报显示海外业务实现两位数以上增长。 国内市场方面，维力医疗进行产品管线升级，如麻醉领域推出可视双支 等 ...

证券代码：603309 证券简称：维力医疗 公告编号：2025-055 广州维力医疗器械股份有限公司 关于子公司产品获得二类医疗器械 注册证的公告 广州维力医疗器械股份有限公司（以下简称"公司"）控股子公司苏州麦德迅医疗科技有限公司（以下简 称"苏州麦德迅"）于近日收到江苏省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体 情况如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、医疗器械注册证的具体情况 注册证编号：苏械注准20252061723 注册人名称：苏州麦德迅医疗科技有限公司 注册人住所：苏州高新区科灵路8号2号楼3层西侧 生产地址：江苏省苏州市高新区科灵路8号2号楼2层2232,江苏省苏州市高新区科灵路8号2号楼3层西侧 特此公告。 适用范围：图像处理器与广州维力医疗器械股份有限公司(含子公司)可视产品配套使用，用于在人体体 腔诊断治疗、手术中有效显示摄像头所观察视场区域的影像。 批准日期：2025年09月02日 有效期至：2030年09月01日 二、对公司的影响 该产品临床上与公司及公司控股子公 ...

Group 1 - The core point of the article is that Weili Medical (603309) announced that its subsidiary, Suzhou Medtronic Medical Technology Co., Ltd., has received a medical device registration certificate from the Jiangsu Provincial Drug Administration for its image processor product [1] Group 2 - The product name registered is "Image Processor" [1] - The announcement was made on the evening of September 4 [1] - The registration certificate is a significant regulatory milestone for the company [1]

Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]

Core Viewpoint - Weili Medical (603309.SH) announced that its subsidiary, Suzhou Medtronic Medical Technology Co., Ltd., has received a Class II medical device registration certificate for its image processor product, which enhances the competitiveness of the company's visual products in the market [1]. Group 1 - The product is designed for clinical use in displaying images of the observation field during diagnosis and treatment in human body cavities and surgeries [1]. - The registration certificate was issued by the Jiangsu Provincial Drug Administration, indicating regulatory approval for the product [1]. - The approval is expected to have a positive impact on the company's operations and market position [1].

Core Viewpoint - Weili Medical (603309.SH) announced that its subsidiary, Suzhou Medtronic Medical Technology Co., Ltd., has received the Medical Device Registration Certificate from the Jiangsu Provincial Drug Administration for its image processor product, which enhances the competitiveness of the company's visual products in the market [1] Group 1 - The product is designed for clinical use in conjunction with the company's visual products, effectively displaying images of the observed field during diagnosis and surgery [1] - The acquisition of the medical device registration certificate is expected to have a positive impact on the company's operations [1]

Core Viewpoint - The company, Weili Medical (603309.SH), has received a medical device registration certificate from the Jiangsu Provincial Drug Administration for its image processor product, which is designed for use in conjunction with the company's visual products during diagnostic and surgical procedures [1]. Group 1 - The product is intended to effectively display images of the observed field during diagnosis and treatment within the human body [1]. - The image processor will be utilized in clinical settings alongside the company's existing visual products [1]. - The approval from the regulatory authority enhances the company's product portfolio and potential market offerings in the medical device sector [1].

Group 1 - The company, Weili Medical (603309.SH), announced that its subsidiary, Suzhou Medtronic Medical Technology Co., Ltd. (referred to as "Suzhou Medtronic"), has recently received a Medical Device Registration Certificate from the Jiangsu Provincial Drug Administration [1] - The product named "Image Processor" is designed to be used in conjunction with the company's and its subsidiaries' visual products for effective display of the imaging area observed by the camera during diagnosis and treatment in human body cavities and surgeries [1]

证券代码：603309 证券简称：维力医疗 公告编号：2025-055 广州维力医疗器械股份有限公司 广州维力医疗器械股份有限公司（以下简称"公司"）控股子公司苏州麦德迅医 疗科技有限公司（以下简称"苏州麦德迅"）于近日收到江苏省药品监督管理局颁发 的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 关于子公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 有效期至：2030年09月01日 二、对公司的影响 注册证编号：苏械注准 20252061723 注册人名称：苏州麦德迅医疗科技有限公司 注册人住所：苏州高新区科灵路 8 号 2 号楼 3 层西侧 生产地址：江苏省苏州市高新区科灵路 8 号 2 号楼 2 层 2232,江苏省苏州市高 新区科灵路 8 号 2 号楼 3 层西侧 产品名称：图像处理器 结构及组成：图像处理器由显示屏、电源适配器、图像处理模块(图像处理模块 分有线连接和无线连接两种)、配件组成。配件包含显示屏夹座和六角螺钉。 适用范围：图像处理器与广 ...

Core Viewpoint - Chinese companies are accelerating their expansion into the Southeast Asian market, exemplified by Weili Medical's establishment of its first overseas production base in Indonesia [1] Group 1: Company Expansion - Weili Medical, a leading company in the medical catheter field, has initiated the construction of its first overseas production facility in Indonesia, driven by local population benefits and healthcare infrastructure needs [1][4] - The logistics partner, Yuexi International, is providing comprehensive compliance logistics solutions to support Weili Medical's overseas expansion [3][5] Group 2: Compliance Challenges - Weili Medical faces compliance challenges related to cross-border logistics, including the import qualifications for construction materials and navigating Indonesia's complex customs policies [4][6] - Yuexi International emphasizes the importance of ensuring compliance throughout the entire logistics chain, not just in transportation [5] Group 3: Customized Solutions - Yuexi International has developed a customized compliance checklist for Weili Medical, addressing the specific regulatory requirements of the medical device industry in Indonesia [5][6] - The company utilizes its extensive knowledge of ASEAN countries' tariff policies and trade agreements to provide tailored solutions that effectively reduce logistics costs for Weili Medical [6][7] Group 4: Future Outlook - Yuexi International aims to continuously optimize its service offerings and deepen its localization strategy to provide precise and efficient compliance support for Chinese companies entering the ASEAN market [7] - The partnership with Weili Medical serves as a practical example of Yuexi International's commitment to assisting Chinese brands in their global expansion efforts [7]